Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech
An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech

Cardiology

  • Article

    Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients

    May 1, 2025

    Clinical question: Are there alternatives to statins for primary prevention? Background: Statins that lower low-density lipoprotein (LDL) cholesterol are major therapeutics in reducing both primary...

  • Article

    Beta-Blocker Interruption or Continuation after Myocardial Infarction

    May 1, 2025

    Clinical question: Is the interrupted use of a beta-blocker non-inferior to its continued use in patients with a history of myocardial infarction (MI)? Background: Patients with MI are often started...

  • Article

    Can Salt Stir the Pot? Sodium’s Effect on Heart Failure Clinical Outcomes

    April 1, 2025

    Clinical question: Is there an association between baseline dietary sodium intake and clinical outcomes in heart failure? Background: Dietary sodium restriction is common advice for patients with...

  • Article

    Comparative Effectiveness and Safety of Apixaban, Rivaroxaban, and Warfarin in Patients with Cirrhosis and AF

    March 4, 2025

    Clinical question: What is the effectiveness and safety of apixaban, rivaroxaban, and warfarin in patients with cirrhosis and atrial fibrillation? Background: The use of direct oral anticoagulants...

  • Article

    Finerenone Reduces HF Events in Patients with Preserved Ejection Fraction

    March 4, 2025

    Clinical question: Does finerenone improve outcomes in patients with heart failure (HF) with mildly reduced or preserved ejection fraction? Background: Steroidal mineralocorticoid receptor...

  • Article

    Empagliflozin After Acute Myocardial Infarction

    March 4, 2025

    Clinical question: Does empagliflozin improve cardiovascular outcomes in patients who have had an acute myocardial infarction? Background: Studies have shown that empagliflozin improves...

  • Article

    Safety of Diltiazem in Patients Taking Apixaban or Rivaroxaban

    March 4, 2025

    Clinical question: Does diltiazem increase the risk of major bleeding in patients on apixaban or rivaroxaban? Background: Diltiazem is a potent CYP3A4 inhibitor and a mild P-glycoprotein inhibitor....

  • Article

    Coding Corner: Talk the Talk, Bill the Bill: Navigating Advance Care Discussion Billing

    January 1, 2025

    A 75-year-old woman with a previous medical history of high blood pressure, diabetes mellitus, stage 4 chronic kidney disease, and lung cancer was admitted to the hospital with chest pain and...

  • Article

    Empagliflozin After Acute Myocardial Infarction (EMPACT-MI)

    January 1, 2025

    Clinical question: Does starting empagliflozin for patients with acute myocardial infarction (AMI) and new onset systolic heart failure (HF) or congestive symptoms reduce the risk of first...

  • Article

    Higher Rates of Major Hemorrhage with Rivaroxaban and Warfarin

    December 2, 2024

    Clinical question: How effective and safe are apixaban versus rivaroxaban versus warfarin in patients with cirrhosis and nonvalvular atrial fibrillation (AF)? Background: Apixaban, rivaroxaban, and...

1 2 3 … 79Next
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
fa-facebookfa-linkedinfa-instagramfa-youtube-playfa-commentfa-envelopefa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.
    ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences